Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Analyst Ratings

Analyst Ratings

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Downgrades
  • Top Stories

MetLife-Spinoff Brighthouse Financial Impresses Analyst With Business Mix Improvements

By Priya Nigam
June 17, 12:47 PM
Analyst upgrades Brighthouse Financial, citing gradual business mix improvement and strong capital position. Stock has lost 23% YTD but trading at reasonable free cash flow yield.

BHF

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Health Care
  • Initiation
  • Long Ideas
  • Movers
  • Top Stories
  • Trading Ideas

Legend Biotech’s Cancer Drug, ‘The Most Attractive Product,’ Set For Growth: Analyst

By Priya Nigam
June 17, 12:15 PM
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.

JNJ

Read More
4 minute read
  • Analyst Ratings

The Analyst Verdict: Cloudflare In The Eyes Of 23 Experts

By Benzinga Insights
June 17, 12:01 PM
Throughout the last three months, 23 analysts have evaluated Cloudflare (NYSE:NET), offering a diverse set of opinions from…

NET

Read More
4 minute read
  • Analyst Ratings

4 Analysts Have This To Say About PagSeguro Digital

By Benzinga Insights
June 17, 12:00 PM
4 analysts have shared their evaluations of PagSeguro Digital (NYSE:PAGS) during the recent three months, expressing a mix…

PAGS

Read More
3 minute read
  • Analyst Ratings

Beyond The Numbers: 8 Analysts Discuss Palantir Technologies Stock

By Benzinga Insights
June 17, 12:00 PM
During the last three months, 8 analysts shared their evaluations of Palantir Technologies (NYSE:PLTR), revealing diverse outlooks from…

PLTR

Read More
3 minute read
  • Analyst Ratings

Analyst Expectations For Citigroup’s Future

By Benzinga Insights
June 17, 12:00 PM
Citigroup (NYSE:C) has been analyzed by 9 analysts in the last three months, revealing a diverse range of…

C

Read More
4 minute read
  • Analyst Ratings

6 Analysts Assess AG Mortgage IT: What You Need To Know

By Benzinga Insights
June 17, 12:00 PM
AG Mortgage IT (NYSE:MITT) has been analyzed by 6 analysts in the last three months, revealing a diverse…

MITT

Read More
3 minute read
  • Analyst Ratings

Critical Insights From Southwest Airlines Analyst Ratings: What You Need To Know

By Benzinga Insights
June 17, 12:00 PM
12 analysts have expressed a variety of opinions on Southwest Airlines (NYSE:LUV) over the past quarter, offering a…

LUV

Read More
4 minute read
  • Analyst Ratings

The Latest Analyst Ratings For Gaming and Leisure Props

By Benzinga Insights
June 17, 11:01 AM
Throughout the last three months, 9 analysts have evaluated Gaming and Leisure Props (NASDAQ:GLPI), offering a diverse set…

GLPI

Read More
4 minute read
  • Analyst Ratings

What Analysts Are Saying About UDR Stock

By Benzinga Insights
June 17, 11:01 AM
In the latest quarter, 13 analysts provided ratings for UDR (NYSE:UDR), showcasing a mix of bullish and bearish…

UDR

Posts pagination

Previous 1 … 13 14 15 … 4,420 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service